SynthesisPloS one2026
Asymptomatic gallstones: Cumulative incidence proportion, incidence rate, and risk factors for symptoms development: Systematic review and meta-analysis.
Synthesis in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThis review aims to evaluate the cumulative incidence proportion, incidence rate, and risk factors for progression of incidentally diagnosed, asymptomatic gallstones to symptomatic gallstone disease (GSD) and associated complications.
designSystematic Review and Meta-Analysis. DATA SOURCE: Four electronic databases were searched (PubMed, Scopus, Web of Science, and ScienceDirect) with no start date restriction, up to July 2025. ELIGIBILITY CRITERIA: Inclusion criteria: patients who were diagnosed with gallstones incidentally. Exclusion criteria: known history of GSD, patients who have undergone bariatric surgery or cholecystectomy, recurrence of gallstones, pregnancy, estrogen therapy, pediatric age group, review, case report, case series, editorial, letters, and abstracts. DATA EXTRACTION AND SYNTHESIS: This review is registered with PROSPERO (CRD42024526889). Primary screening by title and abstract was conducted in Rayyan; full-text screening was performed, and the references of the included studies were manually searched for relevant papers. Data were extracted into an Excel sheet, and the meta-analysis was conducted using RStudio. Single-arm outcomes were summarized in proportion, and comparative outcomes were summarized in Risk Ratio (RR) for categorical outcomes and mean difference for continuous ones. Heterogeneity was evaluated using the I statistic and the Q test.
resultsEight cohort studies, reported in 9, with a total of 25,924 participants, were included. The cumulative incidence proportion of symptomatic progression was 0.10, 95% CI: [[0.10; 0.11]] at 5 years, 0.19, 95% CI: [0.14; 0.25] at 10 years, and 0.26, 95% CI: [0.12; 0.40] at 15 years. Alcohol consumption (RR: 1.32, 95% CI: [1.27; 1.38]) and hyperlipidemia (RR: 1.19, 95% CI: [1.07; 1.32]) were identified as risk factors. Chronic liver disease (RR: 0.76, 95% CI: 0.67; 0.87) and male gender (RR: 0.54, 95% CI: 0.33; 0.87) were observed as protective factors.
conclusionThis systematic review examines factors influencing symptomatic progression of ASG and guides the identification of high-risk patients who may benefit from prophylactic measures such as cholecystectomy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.